BlossomHill Therapeutics, Inc. (BLSM)

Data as of Aug 12, 2026, from SEC Form 4 filings.

Net insider buying (90d)Watch BLSM

See up to 3 months of BLSM. The 7-day demo opens the 1M and 3M ranges and puts BLSM on your watchlist.

Latest BLSM insider trades

Carl L. Gordon - Director
Open-market purchase$10.00M
Aug 10, 2026
ORBIMED ADVISORS LLC - Director

About BlossomHill Therapeutics, Inc. (BLSM)

BlossomHill Therapeutics, Inc. is an SEC registrant, filing under CIK 0001839970, classified as pharmaceutical preparations. It is grouped with Health Care companies on this site. Its offering priced on 7 August 2026 and it trades on NASDAQ.

Sector: Health Care

SEC filings for BLSM on EDGAR

BLSM Form 4 activity by transaction type, last 90 days

Form 4 transaction type	Transactions	Shares	Total value
Open-market purchase	7	1,573,900	$25.18M
Grant or award	8	1,025,708
Other acquisition / disposition	28	23,518,190

BLSM insider transactions (Form 4)

11 Form 4 filings on record, the earliest from Aug 10, 2026, newest first.

Traded	Insider	Transaction	Security	Shares	Price	Value
Aug 10, 2026	Carl L. Gordon - Director	Other	Common Stock	1,039,996	-^{footnote F1}	-
Aug 10, 2026	Carl L. Gordon - Director	Other	Common Stock	1,049,283	-^{footnote F1}	-
Aug 10, 2026	Carl L. Gordon - Director	Open-market purchase	Common Stock	625,000^{footnote F2}	$16.00	$10.00M
Aug 10, 2026	Carl L. Gordon - Director	Other	Series A Preferred Stock	1,039,996	$0.00	-
Aug 10, 2026	Carl L. Gordon - Director	Other	Series B Preferred Stock	1,049,283	$0.00	-
Footnote F1 (price): Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration… Full note on SEC EDGAR Footnote F2 (shares): Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
Aug 10, 2026	ORBIMED ADVISORS LLC - Director	Other	Common Stock	1,039,996	-^{footnote F1}	-
Aug 10, 2026	ORBIMED ADVISORS LLC - Director	Other	Common Stock	1,049,283	-^{footnote F1}	-
Aug 10, 2026	ORBIMED ADVISORS LLC - Director	Open-market purchase	Common Stock	625,000^{footnote F2}	$16.00	$10.00M
Aug 10, 2026	ORBIMED ADVISORS LLC - Director	Other	Series A Preferred Stock	1,039,996	$0.00	-
Aug 10, 2026	ORBIMED ADVISORS LLC - Director	Other	Series B Preferred Stock	1,049,283	$0.00	-
Footnote F1 (price): Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration… Full note on SEC EDGAR Footnote F2 (shares): Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
Aug 10, 2026	John P. Schmid - Director	Open-market purchase	Common Stock	6,000	$16.00	$96K
Aug 6, 2026	Carl L. Gordon - Director	Grant or award	Director Stock Option (Right to Buy)	23,904	$0.00	-
Aug 10, 2026	Bihua Chen - Director	Other	Common Stock	1,599,993^{footnote F1}	-^{footnote F2}	-
Aug 10, 2026	Bihua Chen - Director	Other	Common Stock	1,701,541^{footnote F5}	-^{footnote F2}	-
Aug 10, 2026	Bihua Chen - Director	Open-market purchase	Common Stock	312,500^{footnote F7}	$16.00	$5.00M
Aug 6, 2026	Bihua Chen - Director	Grant or award	Director Stock Option (Right to Buy)	23,904	$0.00	-
Aug 10, 2026	Bihua Chen - Director	Other	Series A Preferred Stock	1,599,993	-^{footnote F2}	-
Aug 10, 2026	Bihua Chen - Director	Other	Series B Preferred Stock	1,701,541	-^{footnote F2}	-
Footnote F1 (shares): Represents (i) 1,228,315 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Fund III (defined below), and (ii) 371,678 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Master Fund (defined below). Footnote F2 (price): Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had… Full note on SEC EDGAR Footnote F5 (shares): Represents (i) 274,912 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Master Fund, (ii) 1,052,460 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund V and (iii) 374,169 shares issued upon… Full note on SEC EDGAR Footnote F7 (shares): The shares purchased are beneficially owned by Master Fund.
Aug 10, 2026	Sundeep Agrawal - Director	Other	Common Stock	578,524	-^{footnote F1}	-
Aug 6, 2026	Sundeep Agrawal - Director	Grant or award	Director Stock Option (Right to Buy)	23,904	$0.00	-
Aug 10, 2026	Sundeep Agrawal - Director	Other	Series B Preferred Stock	578,524	-^{footnote F1}	-
Footnote F1 (price): Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
Aug 10, 2026	Jason A. Keyes - Officer	Open-market purchase	Common Stock	700	$16.00	$11K
Aug 6, 2026	Jason A. Keyes - Officer	Grant or award	Employee Stock Option (Right to Buy)	56,746	$0.00	-
Aug 7, 2026	Vincent Paul Liptak - Officer	Open-market purchase	Common Stock	2,500	$15.80	$40K
Aug 10, 2026	Vincent Paul Liptak - Officer	Open-market purchase	Common Stock	2,200	$16.00	$35K
Aug 10, 2026	Vincent Paul Liptak - Officer	Other	Common Stock	22,687	-^{footnote F1}	-
Aug 6, 2026	Vincent Paul Liptak - Officer	Grant or award	Employee Stock Option (Right to Buy)	46,561	$0.00	-
Aug 10, 2026	Vincent Paul Liptak - Officer	Other	Series B Preferred Stock	22,687	-^{footnote F1}	-
Footnote F1 (price): Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
Aug 6, 2026	Geoffrey Raymond Oxnard - Officer	Grant or award	Employee Stock Option (Right to Buy)	61,783	$0.00	-
Aug 10, 2026	Yishan Li - Officer	Other	Common Stock	1,600,682	-^{footnote F1}	-
Aug 10, 2026	Yishan Li - Officer	Other	Common Stock	113,435	-^{footnote F1}	-
Aug 10, 2026	Yishan Li - Officer	Other	Common Stock	124,779	-^{footnote F1}	-
Aug 6, 2026	Yishan Li - Officer	Grant or award	Employee Stock Option (Right to Buy)	112,701	$0.00	-
Aug 10, 2026	Yishan Li - Officer	Other	Series Angel Preferred Stock	1,600,682	-^{footnote F1}	-
Aug 10, 2026	Yishan Li - Officer	Other	Series B Preferred Stock	113,435	-^{footnote F1}	-
Aug 10, 2026	Yishan Li - Officer	Other	Series B Preferred Stock	124,779	-^{footnote F1}	-
Footnote F1 (price): Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock… Full note on SEC EDGAR
Aug 10, 2026	Jingrong Jean Cui - Officer	Other	Common Stock	1,600,682	-^{footnote F1}	-
Aug 10, 2026	Jingrong Jean Cui - Officer	Other	Common Stock	113,435	-^{footnote F1}	-
Aug 10, 2026	Jingrong Jean Cui - Officer	Other	Common Stock	124,779	-^{footnote F1}	-
Aug 6, 2026	Jingrong Jean Cui - Officer	Grant or award	Employee Stock Option (Right to Buy)	676,205	$0.00	-
Aug 10, 2026	Jingrong Jean Cui - Officer	Other	Series Angel Preferred Stock	1,600,682	-^{footnote F1}	-
Aug 10, 2026	Jingrong Jean Cui - Officer	Other	Series B Preferred Stock	113,435	-^{footnote F1}	-
Aug 10, 2026	Jingrong Jean Cui - Officer	Other	Series B Preferred Stock	124,779	-^{footnote F1}	-
Footnote F1 (price): Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock… Full note on SEC EDGAR

Recent BLSM Form 8-K filings

Read BLSM company news

Sep 18, 2026Item 2.02, 9.01

Read the filing on SEC EDGAR

Sep 15, 2026Item 7.01, 9.01

Read the filing on SEC EDGAR

Aug 10, 2026Item 5.03, 8.01, 9.01

Read the filing on SEC EDGAR

BLSM insider trading FAQ

What is the latest insider trade for BLSM?

BlossomHill Therapeutics, Inc. (BLSM) had 11 insider filings in the last 90 days, with the most recent on 12 August 2026. The full record for BLSM runs to 11 Form 4 filings, the earliest from 10 August 2026. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying BLSM stock?

7 insider purchases of BLSM were filed in the last 90 days, totaling $25.18M.

How many insiders are selling BLSM stock?

No insider sales of BLSM were filed in the last 90 days.

Where can I see BLSM SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects BLSM Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Aug 12, 2026 - Carl L. Gordon view on EDGAR
Aug 12, 2026 - ORBIMED ADVISORS LLC view on EDGAR
Aug 10, 2026 - John P. Schmid view on EDGAR
Aug 10, 2026 - Carl L. Gordon view on EDGAR
Aug 10, 2026 - Bihua Chen view on EDGAR
Aug 10, 2026 - Sundeep Agrawal view on EDGAR
Aug 10, 2026 - Jason A. Keyes view on EDGAR
Aug 10, 2026 - Vincent Paul Liptak view on EDGAR
Aug 10, 2026 - Geoffrey Raymond Oxnard view on EDGAR

Related companies with recent insider activity

Learn more

How to read insider buying signals: What an open-market purchase by an insider can and cannot tell you.
Insider activity in Health Care: Where BLSM's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow BLSM with a 7-day demo

BLSM on your watchlist
Every BLSM Form 4 filing on record
Up to 3 months of BLSM price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Form 4 transaction type

Transactions

Total value

Open-market purchase

1,573,900

$25.18M

Grant or award

1,025,708

Other acquisition / disposition

23,518,190

Traded

Insider

Transaction

Security

Price

Value

Aug 10, 2026

Carl L. Gordon - Director

Other

Common Stock

1,039,996

-^{footnote F1}

Aug 10, 2026

Carl L. Gordon - Director

Other

Common Stock

1,049,283

-^{footnote F1}

Aug 10, 2026

Carl L. Gordon - Director

Open-market purchase

Common Stock

625,000^{footnote F2}

$16.00

$10.00M

Aug 10, 2026

Carl L. Gordon - Director

Other

Series A Preferred Stock

1,039,996

$0.00

Aug 10, 2026

Carl L. Gordon - Director

Other

Series B Preferred Stock

1,049,283

$0.00

Footnote F1 (price): Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration… Full note on SEC EDGAR
Footnote F2 (shares): Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.

Aug 10, 2026

ORBIMED ADVISORS LLC - Director

Other

Common Stock

1,039,996

-^{footnote F1}

Aug 10, 2026

ORBIMED ADVISORS LLC - Director

Other

Common Stock

1,049,283

-^{footnote F1}

Aug 10, 2026

ORBIMED ADVISORS LLC - Director

Open-market purchase

Common Stock

625,000^{footnote F2}

$16.00

$10.00M

Aug 10, 2026

ORBIMED ADVISORS LLC - Director

Other

Series A Preferred Stock

1,039,996

$0.00

Aug 10, 2026

ORBIMED ADVISORS LLC - Director

Other

Series B Preferred Stock

1,049,283

$0.00

Footnote F1 (price): Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration… Full note on SEC EDGAR
Footnote F2 (shares): Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.

Aug 10, 2026

John P. Schmid - Director

Open-market purchase

Common Stock

6,000

$16.00

$96K

Aug 6, 2026

Carl L. Gordon - Director

Grant or award

Director Stock Option (Right to Buy)

23,904

$0.00

Aug 10, 2026

Bihua Chen - Director

Other

Common Stock

1,599,993^{footnote F1}

-^{footnote F2}

Aug 10, 2026

Bihua Chen - Director

Other

Common Stock

1,701,541^{footnote F5}

-^{footnote F2}

Aug 10, 2026

Bihua Chen - Director

Open-market purchase

Common Stock

312,500^{footnote F7}

$16.00

$5.00M

Aug 6, 2026

Bihua Chen - Director

Grant or award

Director Stock Option (Right to Buy)

23,904

$0.00

Aug 10, 2026

Bihua Chen - Director

Other

Series A Preferred Stock

1,599,993

-^{footnote F2}

Aug 10, 2026

Bihua Chen - Director

Other

Series B Preferred Stock

1,701,541

-^{footnote F2}

Footnote F1 (shares): Represents (i) 1,228,315 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Fund III (defined below), and (ii) 371,678 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Master Fund (defined below).
Footnote F2 (price): Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had… Full note on SEC EDGAR
Footnote F5 (shares): Represents (i) 274,912 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Master Fund, (ii) 1,052,460 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund V and (iii) 374,169 shares issued upon… Full note on SEC EDGAR
Footnote F7 (shares): The shares purchased are beneficially owned by Master Fund.

Aug 10, 2026

Sundeep Agrawal - Director

Other

Common Stock

578,524

-^{footnote F1}

Aug 6, 2026

Sundeep Agrawal - Director

Grant or award

Director Stock Option (Right to Buy)

23,904

$0.00

Aug 10, 2026

Sundeep Agrawal - Director

Other

Series B Preferred Stock

578,524

-^{footnote F1}

Footnote F1 (price): Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

Aug 10, 2026

Jason A. Keyes - Officer

Open-market purchase

Common Stock

700

$16.00

$11K

Aug 6, 2026

Jason A. Keyes - Officer

Grant or award

Employee Stock Option (Right to Buy)

56,746

$0.00

Aug 7, 2026

Vincent Paul Liptak - Officer

Open-market purchase

Common Stock

2,500

$15.80

$40K

Aug 10, 2026

Vincent Paul Liptak - Officer

Open-market purchase

Common Stock

2,200

$16.00

$35K

Aug 10, 2026

Vincent Paul Liptak - Officer

Other

Common Stock

22,687

-^{footnote F1}

Aug 6, 2026

Vincent Paul Liptak - Officer

Grant or award

Employee Stock Option (Right to Buy)

46,561

$0.00

Aug 10, 2026

Vincent Paul Liptak - Officer

Other

Series B Preferred Stock

22,687

-^{footnote F1}

Footnote F1 (price): Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

Aug 6, 2026

Geoffrey Raymond Oxnard - Officer

Grant or award

Employee Stock Option (Right to Buy)

61,783

$0.00

Aug 10, 2026

Yishan Li - Officer

Other

Common Stock

1,600,682

-^{footnote F1}

Aug 10, 2026

Yishan Li - Officer

Other

Common Stock

113,435

-^{footnote F1}

Aug 10, 2026

Yishan Li - Officer

Other

Common Stock

124,779

-^{footnote F1}

Aug 6, 2026

Yishan Li - Officer

Grant or award

Employee Stock Option (Right to Buy)

112,701

$0.00

Aug 10, 2026

Yishan Li - Officer

Other

Series Angel Preferred Stock

1,600,682

-^{footnote F1}

Aug 10, 2026

Yishan Li - Officer

Other

Series B Preferred Stock

113,435

-^{footnote F1}

Aug 10, 2026

Yishan Li - Officer

Other

Series B Preferred Stock

124,779

-^{footnote F1}

Footnote F1 (price): Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock… Full note on SEC EDGAR

Aug 10, 2026

Jingrong Jean Cui - Officer

Other

Common Stock

1,600,682

-^{footnote F1}

Aug 10, 2026

Jingrong Jean Cui - Officer

Other

Common Stock

113,435

-^{footnote F1}

Aug 10, 2026

Jingrong Jean Cui - Officer

Other

Common Stock

124,779

-^{footnote F1}

Aug 6, 2026

Jingrong Jean Cui - Officer

Grant or award

Employee Stock Option (Right to Buy)

676,205

$0.00

Aug 10, 2026

Jingrong Jean Cui - Officer

Other

Series Angel Preferred Stock

1,600,682

-^{footnote F1}

Aug 10, 2026

Jingrong Jean Cui - Officer

Other

Series B Preferred Stock

113,435

-^{footnote F1}

Aug 10, 2026

Jingrong Jean Cui - Officer

Other

Series B Preferred Stock

124,779

-^{footnote F1}

Footnote F1 (price): Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock… Full note on SEC EDGAR